Pretax income is the income that a company earns before paying income taxes. Medigen Biotechnology's pretax income for the
three
months ended in Dec. 2024 was NT$-37 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-113 Mil.
Medigen Biotechnology's pretax margin was -11.13%.
During the past 13 years, Medigen Biotechnology's highest Pretax Margin was 28.98%. The lowest was -233.44%. And the median was -156.60%.
Medigen Biotechnology Pre-Tax Income Historical Data
The historical data trend for Medigen Biotechnology's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medigen Biotechnology's Pre-Tax Income
For the Biotechnology subindustry, Medigen Biotechnology's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Biotechnology's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Medigen Biotechnology's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-113 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology (ROCO:3176) Pre-Tax Income Explanation
Medigen Biotechnology's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
During the past 13 years, Medigen Biotechnology's highest Pretax Margin was 28.98%. The lowest was -233.44%. And the median was -156.60%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigen Biotechnology Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Medigen Biotechnology's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:3176 has been successfully added to your 